Wetterskog et al. identified NIK and IKKβ binding protein (NIBP) as a mediator of lapatinib resistance by studying HER2-amplified primary tumors and cell lines using a high throughput lapatinib small interfering RNA sensitivity screen, with a library targeting 369 genes recurrently amplified and overexpressed in HER2-positive breast cancer (240). Here, ERBB2 is linked to breast carcinoma.